Table 1.

Summary of Adherence with Ingestible Sensor Use.

Disease State	Authors	Patient Population	Study Design (Sample Size)	Medication Adherence (%) with Ingestible Sensor
Cardiovascular
	Frias et al. [22]	Uncontrolled Hypertension and Type II Diabetes	Open-label cluster-randomized study (N = 109)	≥80%
	Dicarlo et al. [37]	Hypertension	Feasibility study (N = 37)	90%
Psychiatry
	Kane et al. [27]	Bipolar Disorder and Schizophrenia	Observational study (N = 28)	74%
	Kopelowicz et al. [28]	Bipolar I Disorder, Major Depressive Disorder, Schizophrenia	Open-label, multicenter pilot study (N = 49)	88.6%
	Peters-Strickland et al. [41]	Schizophrenia	Multi-center, open-label phase IIa study (N = 67)	73.9%
Transplant
	Eisenberger et al. [36]	Kidney Transplant	Open-label single-arm (N = 20)	99.4%